Accelerating Immunology Drug and Adjuvant Discovery
Digital Immunology defines the nexus of organs on a chip, biomaterials, and AI, enabled by recent breakthrough in Science, AI, and Technology
Approach
RECENT BREAKTHROUGHS IN IMMUNOTHERAPIES, BIOMATERIALS AND HIGH THROUGHPUT ORGANOID TESTING ARE ENABLING:
-
New cures for cancer and other diseases, marshalling the patient’s own immune system through immune modulation
-
Advances in precision medicine thanks to biomaterials that are programmed to only target specific cells and throttle drug delivery, reducing side effects, improving adjuvancy, and drastically reducing drug/vaccine dosage
-
Rapid, high replicability, test results, leveraging massive data collection and advanced AI, thanks to the high throughput organoid test platforms
Impact
UNPRECEDENTED IMPACT AT HUMANITARIAN AND ECONOMIC LEVELS:
-
Increased vaccine efficacy and global distribution
-
Accelerated drug discovery process
-
Enabling programmatic therapies
About Us
Digital Immunology was founded by senior professionals with proven track records, and extensive networks in R&D, Tech & AI, Business Operations, and Investing. We believe that rapidly accelerating drug and adjuvant technology is key to delivering equitable access to healthcare globally.